

NEWS RELEASE

Local Business Owner, Alethea Wieland, Named to National Small Business Association (NSBA) Leadership Council and Participant in the Small Business Technology Council (SBTC)

Pittsburgh, PA – April 18, 2022. **FOR IMMEDIATE RELEASE**

Alethea Wieland, President of Clinical Research Strategies, LLC (“CRS”), from Wexford, PA, was recently named to the National Small Business Association (NSBA) Leadership Council and participant in the Small Business Technology Council (SBTC). NSBA is the nation’s oldest small-business advocacy organization and operates on a staunchly nonpartisan basis.

SBTC members are a diverse group of technology companies who are fighting for an economic environment that promotes high technology businesses. Through this alliance, Ms. Wieland will help promote and protect the Small Business Innovation Research program (SBIR), and the Small Business Technology Transfer program (STTR), two of the most effective and successful innovation programs in the federal government. The SBIR advocates on behalf of all small technology and R&D firms on a wide range of issues, including intellectual property protections, data rights, regulatory reform, cyber-security compliance and government contracting.

Ms. Wieland, a recognized leader in the small-business community, joins the NSBA Leadership Council alongside other small-business advocates from across the country as they work to promote the interests of small business to policymakers in Washington, D.C.

“As a small-business owner on the global life sciences stage, I see daily the importance of being involved and active when it comes to laws and regulation, but more importantly what impacts the livelihoods of small businesses, the life-blood of many communities across the United States post-Covid,” stated Wieland. “Joining NSBA’s Leadership Council and participating on the SBTC will enable me to take our collective small-business message to the people that need to hear it most: Congress.”

Alethea Wieland is a 30-year veteran in life sciences who has devoted her career to regulatory strategy and submissions, regulatory science and policy reform, clinical operations, and corporate compliance. Her areas of expertise include analyzing the intersection of healthcare innovation and policy; developing sustainable corporate affairs programs and policies; training and managing resilient, high-performing clinical operations teams; mitigating risks of clinical trials; and facilitating transparent, accountable sponsor-CRO partnerships.



Wieland joined the NSBA Leadership Council as part of her efforts to tackle the many critical issues facing small business, including tax reform, regulatory restraint, health care costs and how the current administration's New World Order (NWO) impacts on small business. The NSBA Leadership Council is focused on providing valuable networking between small-business advocates from across the country while ensuring small business a seat at the table as Congress and regulators take up key small-business proposals.

"I am proud to have Alethea Wieland as part of our Leadership Council," stated NSBA President and CEO Todd McCracken. "She came to us highly recommended and I look forward our coordinated efforts for years to come."

Please click here to learn more about [Clinical Research Strategies, LLC](#).

For more on the NSBA Leadership Council, please visit www.nsba.biz.

About Clinical Research Strategies, LLC ("CRS")

CRS is a specialty CRO and executive management consulting firm that fits-for-purpose veteran life sciences executives, attorneys, regulatory scientists and strategists, clinical operations, project management, quality assurance engineers, and sales and marketing teams to take on the biggest challenges for start-up, mid-sized, and large life sciences companies, many of whom are developing novel, first-in-class drugs, biologics, diagnostics and medical devices, or software as a medical device (SaMD). Service areas are clinical trials, Functional Service Provider (FSP) models, selection and management of CROs, regulatory compliance strategy and submissions, QMS, EU MDR and GDPR, rescue trials, TMF, risk mitigation and remediation, training high-performing teams, staffing solutions, and decentralized trials. Indications represented are precision medicine, immuno-oncology, central nervous system, infectious diseases, respiratory diseases, orthopedics, de novo devices, digital health and mobile apps, reproductive health, regenerative medicine, cardiology, major depressive disorder, opioid-sparing pain, cannabis, radiology, and critical care. CRS is a qualified service provider for federal grants.

###

Media Contact:

Ron MacDonald

Step2Branding and Design

ronmac@step2branding.com

+1 724.814.4067